This study is looking at how a medication called tirzepatide might help adults who have alcohol use disorder (AUD) and are also overweight or have obesity. You could be eligible if you are between 21 and 65 years old, meet specific criteria for AUD, and have a Body Mass Index (BMI) of 27 or higher. Participants will receive weekly injections of either tirzepatide (2.5mg or 5.0mg) or a placebo (an inactive substance). The main goal is to see if tirzepatide reduces the number of heavy drinking days over the last four weeks of treatment. The study aims to enroll 42 participants, but its current recruitment status is unclear.

Study design

This is a Phase 2 randomized controlled trial, meaning participants will be randomly assigned to receive either tirzepatide or a placebo. The study plans to enroll 42 participants.

What's involved

You would need to attend weekly medication visits and complete all study procedures. The primary endpoint is measured at the last 4 weeks of treatment (Weeks 5-8).

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at the last 4 weeks of treatment (Weeks 5-8), but further follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.